Particle.news

FDA Approves Lipfendra, First Oral PCSK9 Pill for High LDL Cholesterol

Regulators based the decision on large LDL‑C reductions in two randomized trials with a large cardiovascular outcomes study still underway

Overview

  • The FDA cleared Lipfendra (enlicitide) for adults with high LDL cholesterol after two double‑blind, placebo‑controlled trials of about 3,200 people showed average LDL‑C drops of about 56% and 59% at 24 weeks when added to maximally tolerated statins.
  • Lipfendra is the first oral drug to block PCSK9, a liver protein that lowers the number of receptors that remove LDL from blood, and it can be used instead of or together with statins and other cholesterol drugs.
  • Trial safety was broadly similar to placebo in one study while the HeFH trial reported more cases of diarrhea and dizziness, indicating generally tolerable side effects but not a risk‑free profile.
  • Merck set a list price of $10.50 per day and said the pill will reach pharmacies within weeks, but real patient access will depend on insurer coverage, prior authorization rules, and company assistance programs.
  • Doctors and guideline groups see Lipfendra as a new tool to help more people reach lower LDL targets, yet definitive proof that it cuts heart attacks and strokes must wait for the ongoing outcomes trial and real‑world uptake data.